News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Lab Leaders and AI Experts Back Mandatory DNA Synthesis Screening
A coalition of biotech CEOs, AI researchers, and national security officials signed an open letter June 3 calling on Congress to mandate screening of synthetic DNA orders. Here's what the guardrail covers and why the timing matters.
Cells use antibody-tagged viruses to trigger self-defense autophagy
Researchers mapped a previously unknown intracellular pathway where TRIM21 protein flags antibody-coated bacteria and viruses for digestion, blocking Salmonella and adenovirus infection inside cells.
D&D-seq Maps Weak Protein-DNA Contacts in Single Cells
A new method using base editing and nanobodies captures fleeting transcription factor binding that traditional ChIP-seq misses. Researchers can now profile regulatory proteins in individual cells alongside gene expression and chromatin data.
Pharma's PD-1/VEGF bet may target wrong cancer. Liver shows more promise than lung.
Drug makers are chasing PD-1/VEGF bispecifics in lung cancer, but clinical evidence suggests the liver is a stronger indication. Here's what that shift means for your pipeline.
House moves to block China biotech deals after Pfizer, Bristol Myers moves
A bipartisan bill would add biotechnology to the COINS Act, restricting Chinese investment in U.S. drug development. The push follows major pharma acquisitions and U.S. concerns about China's drugmaking progress.
Manipal Health commits Rs 816 crore on 30-year Bengaluru hospital lease
Hospital operator backed by Temasek and TPG signed a 2.45 lakh sq ft lease in Yelahanka with 10% and 15% escalations built in. Signals acceleration of urban property strategy.
Paras Healthcare files Rs 1,800-cr IPO, plans 800 new beds by 2028
Paras Healthcare, which operates 2,211 beds across six states, filed IPO papers with Sebi on Thursday. The Gurugram hospital chain plans to expand capacity to 3,011 beds within two years.
ADC Therapeutics shares crash 50% over blood cancer trial deaths
ADC Therapeutics' stock plunged after a Phase 3 trial showed a death rate one analyst called unacceptable to physicians and regulators. What the safety signal means for the drug candidate.
Alnylam bets $2B on Inceptive's AI for RNA drug discovery
Alnylam and AI startup Inceptive inked a deal valued up to $2 billion to accelerate RNA therapeutic development. The partnership taps machine learning to filter candidate drugs faster.
Pharma's PD-1/VEGF bet targets lung cancer. Liver data suggests a mismatch.
Drugmakers are investing heavily in PD-1/VEGF bispecific antibodies for lung cancer, but clinical evidence points to liver tumors as the more promising indication. A strategic misalignment that could waste years of development.
Medtronic files for Hugo robot clearance in new surgery types
Medtronic is pursuing FDA 510(k) clearance to expand its Hugo surgical robot into additional procedures. The move would let it compete with Intuitive's da Vinci in core robotic surgery markets.
Diabetes device makers race to kill meal announcements—but safety trade-offs loom
Insulet, MiniMed and Tandem Diabetes Care are all developing fully closed-loop systems that remove manual meal logging. The automation promise comes with control and data gaps practitioners need to understand.